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microtubule-associated protein 1 light chain 3; MCB, monochlorobimane; MEFs, mouse embryonic fibroblasts; MbCD, methyl-
b-cyclodextrin; MnTBAP, manganese [III] tetrakis (4-benzoic acid) porphyrin; mtRFP, mitochondrially targeted red fluorescent pro-
tein; nsc, nonsilencing control; NRF1, nuclear respiratory factor 1; OMM, outer mitochondrial membrane; PBS, phosphate-buffered
saline; PINK1, PTEN-induced putative kinase 1; PRKCE, protein kinase C, epsilon; RM, recording medium; ROS, reactive oxygen
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The 18-kDa TSPO (translocator protein) localizes on the outer mitochondrial membrane (OMM) and participates in
cholesterol transport. Here, we report that TSPO inhibits mitochondrial autophagy downstream of the PINK1-PARK2
pathway, preventing essential ubiquitination of proteins. TSPO abolishes mitochondrial relocation of SQSTM1/p62
(sequestosome 1), and consequently that of the autophagic marker LC3 (microtubule-associated protein 1 light chain
3), thus leading to an accumulation of dysfunctional mitochondria, altering the appearance of the network.
Independent of cholesterol regulation, the modulation of mitophagy by TSPO is instead dependent on VDAC1 (voltage-
dependent anion channel 1), to which TSPO binds, reducing mitochondrial coupling and promoting an overproduction
of reactive oxygen species (ROS) that counteracts PARK2-mediated ubiquitination of proteins. These data identify TSPO
as a novel element in the regulation of mitochondrial quality control by autophagy, and demonstrate the importance
for cell homeostasis of its expression ratio with VDAC1.
Introduction
Discovered in 1977, TSPO (translocator protein) was first
characterized as a high affinity benzodiazepine binding site in
peripheral tissues.1 It was initially named the peripheral benzodi-
azepine receptor (PBR) although it is anatomically and pharma-
cologically different from the central benzodiazepine receptor
(CBR).2 TSPO is evolutionarily conserved and ubiquitously
expressed throughout the body, with elevated expression in ste-
roidogenic endocrine tissues.3-5 This reflects the prominent role
it plays in facilitating the transport of the steroid hormone pre-
cursor cholesterol to the inner mitochondrial membrane.6-8 Its
ubiquitous expression suggests pleiotropic functionality, and
indeed many additional roles have been assigned to TSPO. It is a
suggested component of the mitochondrial permeability transi-
tion pore (mPTP)9 although supporting evidence for this is still
missing.10 A role for TSPO in the execution of apoptosis has
long been proposed and its natural and synthetic ligands i) endo-
zepine,11,12 ii) PK1119513-16 and iii) Ro-5486417 are widely
exploited as chemotherapy co-adjuvants. Other functions linked
to TSPO include: i) the regulation of mitochondrial ATP pro-
duction,18,19 ii) the generation of reactive oxygen species,20,21
and iii) the modulation of Ca2C signaling.22,23 Notably, its pre-
cise role in cell physiology has received relatively little attention,
leaving its contribution to mitochondrial function largely ill-
defined. On the contrary, robust evidence exists for describing a
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role for TSPO in cell pathology: i) TSPO is detected at greater
levels in a number of cancers24-26 in which its expression corre-
lates with disease progression and malignant behavior.27 ii)
TSPO expression is augmented in activated microglia and serves
as an in vivo imaging biomarker of acute and chronic neuroin-
flammation.28,2929 iii) Interestingly, TSPO expression is also
increased in Parkinson disease patients,30,31 in which defective
mitochondrial autophagy is acknowledged as the underlying fea-
ture, thus suggesting a potential involvement of TSPO in mito-
chondrial quality control.
The current mechanistic model of mitophagy requires full-
length PINK1 (PTEN-induced kinase 1) to selectively accumu-
late on the outer membranes of depolarized mitochondria, where
it initiates the recruitment of the cytosolic E3 ubiquitin ligase,
PARK2.32-35 PARK2 ubiquitinates outer mitochondrial mem-
brane proteins and recruits SQSTM1.36,37 Within this model,
the role of proteins constitutively present in the OMM is unclear
and the involvement of the most abundant component, VDAC1,
still controversial.38 It has been suggested that VDAC1 interacts
with PARK2 and is involved in its recruitment and function dur-
ing mitochondrial autophagy;38,39 however, opposing evidence
exists which indicates VDAC1 is dispensable in the process.36 By
being in close proximity with VDAC1 or interacting with this as
proposed previously,40-42 TSPO may be an added element in the
platform of molecules on which the efficiency of PARK2-medi-
ated mitophagy relies. We initially tested this pharmacologically
by employing a synthetic ligand, PK 11195, which proved, how-
ever, to be nonspecific and involved pathways unrelated to
TSPO.43,44 We therefore exploited TSPO molecularly by manip-
ulating its expression to test its effect on the PINK1-PARK2
axis.45 This work shows that TSPO expression when increased
compared to that of VDAC1 limits the efficiency of mitochon-
drial autophagy by increasing the accumulation of ROS, which
leads to a decreased efficiency of ubiquitin-dependent mitochon-
drial protein degradation.
Results
We initially carried out an immunofluorescence analysis in
various mammalian cell lines to confirm the subcellular colocali-
zation of TSPO and VDAC1 in mouse embryonic fibroblasts
(MEFs) (Fig. 1A) and canine mammary gland epithelia (CF35)
(Fig. S1A). In both MEFs and CF35, TSPO exhibited a mito-
chondrial pattern, visualized by discrete colocalization with
VDAC1 consistent with previous studies.41,46
Consequently, we sought to alter the ratio of TSPO:VDAC1
expression by transiently knocking down TSPO with siRNA
(-TSPO) or overexpressing with cDNA (CTSPO). Cells trans-
fected with an empty vector (C) or a nonsilencing siRNA (NSC)
were used as controls. Changes in TSPO expression were con-
firmed via immunoblotting analysis (Fig. 1B) and achieved in
both MEFs (relative to control CTSPO: 1.24§ 0.01 -TSPO:
0.33 § 0.01 NSC 0.96 § 0.03; Fig. 1C) and CF35 (relative to
control CTSPO: 1.37 § 0.10 -TSPO 0.40 § 0.04 NSC 0.90 §
0.04; Fig. S1B, C). Modulation of TSPO was further confirmed
by real-time qRT-PCR studies in CF35 (control: 677842 §
18286, CTSPO: 926736 § 62430, -TSPO: 422042 § 60823,
NSC: 670350 § 4350; Fig. 1D).
In MEFs we then assayed the level of LC3B-II activation, a
lipidated form of LC3B that, localizing on phagophores and
autophagosomes, indicates the degree of autophagic activation.47
During unstimulated conditions, TSPO modulation did not
demonstrate profound differences in the level of LC3B-II when
compared to control (representative blot depicted in Fig. 1E with
quantification reported in F; control: 0.65 § 0.07 CTSPO: 0.61
§ 0.11 -TSPO 0.54 § 0.08 NSC: 0.56 § 0.05). After applica-
tion of the mitochondrial protonophore FCCP (20 mM), which
is commonly used to depolarize mitochondria35,48 and induce
the autophagic sequestration of nonrespiring organelles, the den-
sity ratio of LC3B-II became significantly greater in -TSPO cells
and markedly less in CTSPO cells as shown in Fig. 1E, F (con-
trol: 1.39 § 0.02 CTSPO: 1.02 § 0.0009 -TSPO: 1.86 § 0.10
NSC: 1.39 § 0.011). This was due to the actual production of
autophagosomes and not to autophagic flux, as the result
remained unchanged in the presence of bafilomycin A1
49
(Fig. 1E) (bafilomycin A1, control: 0.87 § 0.12, CTSPO: 0.72
§ 0.04, -TSPO: 0.81§ 0.15, NSC: 0.86§ 0.08; FCCPCbafilo-
mycin A1, control: 1.30 § 0.04, CTSPO: 0.62 § 0.04, -TSPO:
2.78 § 0.26, NSC: 1.70 § 0.10; Fig. 1F). High-resolution con-
focal images of TSPO-modulated CF35 cells cotransfected with
GFP-LC3 and the mitochondria-targeted red fluorescent protein
(mtRFP) (Fig. 2A) allowed us to calculate the degree of colocali-
zation between LC3 puncta and mitochondria (Fig. 2B). At basal
levels, a trend emerged in which -TSPO cells (0.23 § 0.05) dis-
played a greater degree of colocalization than in control (0.17 §
0.04) and in CTSPO cells (0.09 § 0.02), and this was exagger-
ated in the presence of FCCP. The formation of mitochondria-
containing autophagosomes in cells treated with FCCP was sig-
nificantly higher in -TSPO cells (0.48 § 0.05), relative to con-
trols (0.35 § 0.02) and reduced in CTSPO cells (0.19 § 0.05).
The same results were obtained in MEFs (control, basal: 0.19 §
0.021, FCCP: 0.45 § 0.060; CTSPO, basal: 0.17 § 0.014,
FCCP: 0.25 § 0.023; -TSPO, basal: 0.24 § 0.032, CFCCP:
0.62 § 0.060; Fig. S1D and E). We also corroborated this by
performing immunoblotting analysis of ATP5B levels50
(Fig. S1F) which are reduced in MEFs downregulated for TSPO
and to a greater extent went treated with FCCP (Fig. S1G)
(basal, control: 1.00 § 0.01, CTSPO: 1.25 § 0.04, -TSPO:
0.59 § 0.01; FCCP, control: 0.69 § 0.05; CTSPO: 0.80 §
0.03, -TSPO: 0.25 § 0.01). We also inspected whether TSPO
expression influenced macroautophagy and therefore challenged
control (mock-transfected), CTSPO and -TSPO MEFs with
rapamycin,51 and monitored the degree of LC3 activation with-
out and with cotreatment with bafilomycin A1
51 Notably, the
expression level of TSPO did not affect macroautophagy induc-
tion nor the maturation of autophagosomes,51 arguing for an
effect on the mitochondrial type of autophagy (mitophagy) rather
than on the general, non-targeted type (Fig. S2A).
Consequently, we checked the mitochondrial recruitment of
SQSTM1 that, binding directly to LC3, facilitates the degrada-
tion of ubiquitinated protein aggregates by autophagy.52 MEFs,
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transfected with mtRFP, were treated for 4 h with FCCP, immu-
nolabelled for SQSTM1 and assayed for the degree of colocaliza-
tion (Fig. 2C). What emerged from this analysis was that
mitochondrial recruitment of SQSTM1 was reduced in CTSPO
cells (0.82 § 0.04), contrary to control (1.00 § 0.05) and
-TSPO cells (1.24 § 0.08) (Fig. 2D). This, quite notably, was
accompanied by differences in the aggregation of mitochondria,
as determined by the analysis of mtRFP distribution over the
Figure 1. TSPO regulates the autophagy response in FCCP-treated cells. (A) Confocal immunofluorescence microscopy shows that TSPO (green) colocal-
izes with VDAC1 (red) on mitochondria in MEFs. DAPI (blue) is representative of cell nuclei. (B) Western blot to demonstrate modulation of TSPO
(18 kDa) in MEF cells relative to VDAC1 (32 kDa). (C) Graph shows band density analysis (n D 3; P < 0.001). (D) Real time quantitative RT-PCR analysis for
estimation of TspomRNA levels in CF35. (E) Western blot analysis of MEFs treated with bafilomycin A1 (BAF, 100 nM), to inhibit autophagic flux, for 4 h in
the presence and absence of FCCP (20 mM). (F) Graph shows LC3-II:GAPDH ratio band density analysis (n D 3; P < 0.01).
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cellular surface. In CTSPO cells, the aggregation coefficient was
only 0.16 § 0.06 compared to values of 0.50 § 0.11 and 1.58 §
0.20 for control and -TSPO cells, respectively (Fig. 2E).
Having demonstrated the differences in SQSTM1 relocation
to mitochondria according to TSPO expression we next explored
the translocation of the E3 ubiquitin ligase PARK2, which is piv-
otal for the recruitment of SQSTM1 by polyubiquitinating
OMM proteins.53 The translocation of PARK2 was assessed by
transfecting cells modulated for the TSPO-VDAC1 ratio with
PARK2-YFP and by immunostaining for ATP5B to distinguish
mitochondria with and without translocated PARK2 (Fig. 3A).
At basal conditions, PARK2-YFP was uniformly distributed
throughout all conditions and induction of mitophagy with
FCCP triggered a redistribution of PARK2-YFP, which was not
Figure 2. TSPO limits mitochondrial autophagy and SQSTM1 recruitment. (A) Representative images of TSPO-modulated CF35 cells before and after
treatment with FCCP (20 mM) for 30 min. Scale bar D 50 mm. A magnification of the merged images is shown in areas demarcated by the white box.
Scale bar D 5 mm. (B) Quantification of the degree of mtRFP:GFP-LC3 colocaliztion in CF35 cells (n > 10 cells; P < 0.01). (C) MEFs transfected with mtRFP
(red) and treated with FCCP (20 mM) were immunolabeled against SQSTM1 (grayscale). Nuclei were stained with DAPI. White arrows show areas in both
control and -TSPO cells where mitochondria have formed aggregates that colocalize with SQSTM1. (D) Quantification of SQSTM1 localization on mito-
chondria (n> 20 cells; P< 0.01). (E) Evaluation of the mitochondrial aggregation coefficient (determined by the ratio between the mtRFP signal intensity
and the total mitochondrial area) (n > 20 cells; P < 0.001).
2282 Volume 10 Issue 12Autophagy
Figure 3. TSPO leaves unaltered the PINK1-PARK2 signaling pathway. (A) Confocal microscopy depicts MEFs transfected with PARK2-YFP (green) and
immunolabeled against ATP5B of the mitochondrial ATPase (red). DAPI was used to stain nuclei (blue). Scale bars D 20 mm. White lines show areas
selected for fluorescence intensity profiles. (B) Quantification of PARK2 translocation on mitochondria in cells treated with FCCP (n > 20 cells). (C) Repre-
sentative traces of the effects of FCCP on DCm in TSPO-modulated MEFs. (D) Western blot analysis of the accumulation of PINK1 long isoform (66 kDa)
after FCCP treatment in TSPO-modulated MEFs with relative quantification in (E) (n D 3).
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altered by the modulation of TSPO expression (Fig. 3B; control:
0.69 § 0.04, CTSPO: 0.65 § 0.04, -TSPO: 0.56 § 0.05, NSC:
0.54 § 0.07). This was confirmed further by scrutinizing the lev-
els of the endogenous PARK2 via western blot analysis
(Fig. S2B).
These findings indicated that, regardless of TSPO expression,
PARK2 translocates to mitochondria36 while SQSTM1 signaling
is modified. To better assess the behavior of mitochondria under
distinct TSPO expression conditions, we checked whether mito-
chondrial depolarization was impaired and therefore monitored
the rate of the mitochondrial membrane potential (DCm) dissi-
pation with TMRM following FCCP (1 mM) addition, which
was unmodified in its rate despite the TSPO expression ratio
(Fig. 3C). In parallel, we monitored the accumulation of PINK1
in mitochondria (Fig. 3D) and observed no differences, thus
indicating a downstream mechanism through which TSPO can
influence the removal of depolarized mitochondria flagged by
PINK132,33 (Fig. 3E; DMSO PINK1 33 kDa, control: 0.12 §
0.03 CTSPO: 0.21 § 0.003 -TSPO: 0.19 § 0.05; FCCP
PINK1 33 kDa, control: 0.16 § 0.01 CTSPO: 0.34 § 0.01
-TSPO: 0.28 § 0.01; DMSO PINK1 66 kDa, control: 0.52 §
0.02 CTSPO: 0.49 § 0.008 -TSPO: 0.45 § 0.10; FCCP
PINK1 66 kDa, control: 0.83 § 0.06 CTSPO: 0.74 § 0.15
-TSPO: 0.80 § 0.06).
Once associated with mitochondria, PARK2 promotes ubiq-
uitination of OMM proteins, which is a fundamental step for
organelle clearance by autophagy. We explored this by cotrans-
fecting cells with mtRFP and, after exposure to 20 mM FCCP,
immunostaining these with anti-ubiquitin antibody (Fig. S2C).
The results indicate that none of the CTSPO cells were classed as
having mitochondrial ubiquitination; conversely, substantially
more ubiquitination was detected in -TSPO cells (53.45 §
3.69), relative to control (25.37 § 3.20) (Fig. S2D). This was
confirmed via protein gel blot analysis of isolated cross-linked
mitochondrial proteins immunolabeled for ubiquitin in which
FCCP triggered an increase in polyubiquitination in nonsilenc-
ing control (nsc) conditions, that was significantly elevated in
-TSPO cells, particularly at heavier band densities (Fig. 4A). In
Figure 4.Mitochondrial protein ubiquitination is affected by TSPO. (A) Immunoblot of mitochondria isolated from MEFs and transfected with Tspo siRNA
(-) or a nonsilencing control (nsc) to show changes in polyubiquitination before and after FCCP treatment (4 h). (B) As in (A) but with MEFs transfected
with Tspo cDNA (C) or an empty vector (WT). (C) Band density analysis showing the relative increase in mitochondrial polyubiquitin following FCCP treat-
ment (n D 3; P < 0.01). (D) Western blot to demonstrate reduced expression of TSPO in PRKCE¡/¡ MEF cells relative to GAPDH. (E) Graph shows mean
TSPO band density analysis relative to GAPDH loading control (n D 3; P < 0.001). (F) Western blot highlighting mitochondrial ubiquitination in WT and
PRKCE¡/¡ MEF cells before and after treatment with 20 mM FCCP. (G) The graph shows total ubiquitin band density analysis relative to ATP5B loading
control (nD 3; P< 0.05).
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CTSPO samples, ubiquitination was notably reduced after treat-
ment with FCCP (Fig. 4B) when compared to controls (WT).
Band density analysis of polyubiquitin (Fig. 4C), post FCCP
treatment, revealed a decrease in the ratio of ubiquitin to the
loading control (ATP5B) in CTSPO (0.30 § 0.0001) and
increased in -TSPO cells (0.87 § 0.017), relative to the 2 con-
trols (C: 0.71 § 0.018, NSC 0.64 § 0.097). To rule out that
this observed de-ubiquitination is a consequence of alternative
protein degradation pathways we tested the expression levels of
MFN1 (mitofusin 1) and MFN2 (mitofusin 2). These prototypi-
cal components of the mitochondrial outer membrane are tar-
geted for degradation in a proteasome- and PSMD2 (proteasome
[prosome, macropain] 26S subunit, non-ATPase, 2)-dependent
manner, which are required for PARK2-mediated mitoph-
agy.37,54 We found that the expression patterns of both MFN1
and MFN2 were not affected by TSPO expression (Fig. S3B)
showing that PMSD2 and proteasome activity remains intact.
We also recapitulated the deficiency in ubiquitination in
PRKCE (protein kinase C, epsilon/ knockout MEFs. Tspo gene
expression is driven by this kinase,55 leading to a reduction in
endogenous TSPO expression. Immunoblotting analysis of
lysates from PRKCE¡/¡ cells indeed indicated a reduction (0.59
§ 0.06) in TSPO compared to WT control cells (Fig. 4D, E).
This associates with significantly more ubiquitinated mitochon-
drial fractions (2.24 § 0.37) when compared to WT control cells
(1.00 § 0.00) at resting conditions. Equally, in FCCP-treated
conditions considerably more mitochondrial ubiquitination was
observed in PRKCE¡/¡ cells (4.01 § 083) compared to WT
(1.42 § 0.12) (Fig. 4F, G).
As TSPO is known for its role in cholesterol transport, we
wanted to explore whether this property of TSPO was contribut-
ing to the effect on ubiquitination described. We generated a
mutant of the protein by deleting the cholesterol recognition/
interaction amino acid consensus (CRAC) domain from TSPO
(TSPOD150–158) (Fig. 5A). To confirm loss of function, mito-
chondrial cholesterol accumulation was measured via Amplex
Red analysis (Fig. 5B; control: 31706 § 293.5, CTSPO: 37107
§ 1478, CTSPOD150–158: 29308 § 403.5, -TSPO: 27533 §
334.8, NSC: 32127 § 395). MEFs were therefore transfected
with the TSPOD150–158 construct and monitored for the ubiqui-
tination of mitochondrial proteins using ubiquitin-GFP (Ub-
GFP; Fig. 5C). This approach showed that ubiquitination is
largely reduced by the overexpression of TSPO, as expected,
while unchanged by the mutated isoform (» 4 times relative to
control, see Fig. 5C, D; control: 0.052 § 0.01, CTSPO:
0.015§ 0.002, TSPOD150–158 0.008 § 0.003,).
We confirmed this further by applying methyl-b-cyclodex-
trin (MbCD), a lipid microdomain-disrupting agent that indu-
ces mitochondrial cholesterol depletion (0.008 § 0.002;
Fig. 5D).56 However, knowing that an imbalance in the cellular
redox state associates with a limitation of PARK2-mediated
ubiquitination57 and hypothesizing that TSPO may influence
this pathway as its upregulation is linked to increased ROS pro-
duction,21 we investigated whether an antioxidant treatment
could counteract the effects on ubiquitination in TSPO-overex-
pressing cells. And, by using the antioxidant SOD mimicking
agent, MnTBAB,44 the efficient ubiquitination of mitochondrial
proteins was restored in TSPO-overexpressing cells (0.125 §
0.034) compared to untreated CTSPO cells (0.015 § 0.002)
(Fig. 5D). Notably, MnTBAP treatment was also accompanied
by a visible increase in the targeting of mitochondria by auto-
phagosomes following membrane depolarization by FCCP
(DMSO, control: 0.19 § 0.02, CTSPO: 0.09 § 0.007,
CTSPOCMnTBAP: 0.18 § 0.03; FCCP, control: 0.45 §
0.06, CTSPO: 0.18 § 0.03, CTSPOCMnTBAP: 0.37 §
0.017; Fig. 5E with quantification in panel G). Furthermore,
expression of TSPOD150–158 did not modify the translocation of
PARK2 (DMSO – control: 0.31 § 0.03, CTSPO: 0.26 §
0.03, CTSPOD150–158: 0.45 § 0.03; FCCP – control: 0.73 §
0.05, CTSPO: 0.73 § 0.07, CTSPOD150–158: 0.70 § 0.05)
(Fig. 5F with quantification in panel H) consistent with obser-
vations made for the WT protein.
The cytosolic rate of ROS production was measured using the
fluorescent probe dihydroethidium (DHE), which is sensitive to
O2
¡ (superoxide) and is oxidized to the red fluorescent molecule
ethidium. 44 The basal rate of DHE oxidation was elevated in
CTSPO cells (4.70 § 0.34) but was almost undetectable in
-TSPO cells (0.42 § 0.05) compared to controls (1.45 § 0.09)
(Fig. 6A, B). Additionally, TSPOD150–158 increased cytosolic
ROS to a level comparable with overexpression of the WT pro-
tein (Fig. S3A). The levels of reduced, biologically active gluta-
thione (GSH), quantified with the fluorescent dye
monochlorobimane (MCB), further confirmed this observation.
In contrast to ROS, GSH was significantly higher in -TSPO cells
(87.5 § 6.38) compared to control (60.64 § 6.54) (Fig. 6C).
Reduction in ROS metabolism, as seen in -TSPO cells, was thus
coupled with a high ratio of reduced GSH, indicative of a bal-
anced redox system. Interestingly, an increase, although not sta-
tistically significant, in MCB intensity was recorded in CTSPO
cells (74.0 § 4.39) that could imply an adaptive response to
compensate for high basal production of mitochondrial ROS.58
Our analysis of mitochondrial physiology under conditions of
altered TSPO expression was furthered by testing the Ca2C-
dependent production of ATP59 using the mitochondria targeted
isoform of the ATP reporter luciferase (mt-Luc) in C/¡TSPO
cells. The number of luminescent counts, which is proportional
to ATP production,59 was assayed after challenging cells with an
inositol triphosphate-generating stimulus (100 mM ATP;
Fig. 6D). This produced a rise in mitochondrial ATP that was
greater in -TSPO cells (2.00 § 0.02) compared to control (1.45
§ 0.09) and to those overexpressing TSPO (1.24 § 0.0002)
(Fig. 6E).
To establish whether these physiological differences could be
assigned to an increase/decrease in mitochondrial numbers, we
monitored the expression of genes controlling mitochondrial bio-
genesis, namely TFAM (transcription factor A, mitochondrial)
and NRF1 (nuclear respiratory factor 1).60 These remained unaf-
fected despite modulated TSPO level (control, TFAM: 673250
§ 20, NRF1: 261750 § 41; CTSPO: TFAM 858550 § 157,
NRF1 305750 § 547; -TSPO: TFAM 561700 § 63600, NRF1
207250 § 515; NSC: TFAM 754500 § 36800, NRF1 246150
§ 185; Fig. 6F).
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If deregulation of mitochondrial physiology were a conse-
quence of impaired mitophagy, the mitochondrial morphology
would be affected and the network would appear disorganized
with uncontrolled accumulation of organelles. We monitored
this using high-resolution confocal analysis of cells modulated for
TSPO co-expressing the mitochondrially targeted GFP (mtGFP)
(Fig. 6G). The proportion of network volume was calculated rel-
ative to cytosolic volume, determined by staining with the
cytosolic-based fluorescent
dye SNARF-1. The per-
centage of mitochondria
was greater in CTSPO cells
and significantly reduced in
-TSPO cells (control:
27.21%§ 2.45, CTSPO: 34.11%§ 2.70, -TSPO: 14.84%§
1.50 P < 0.01; n > 20; Fig. 6H). Individual mitochondria also
appeared more connected in -TSPO cells compared to the more
disorganized network evident in CTSPO cells (Fig. 6G).
We therefore monitored the mitochondrial accumulation of
the GTPase DNM1L (dynamin 1-like) among the 3 conditions
of TSPO expression before and after treatment with the mitoph-
agy-triggering stimulus FCCP. DNM1L controls the final steps
Figure 5. Antioxidants restore
ubiquitination deficiency in
TSPO overexpressing mito-
chondria. (A) Struc-tural com-
parison of wild type TSPO and
the TSPO CRAC domain dele-
tion mutant. TSPO transmem-
brane doma-ins are indicated
in black. (B) Evaluation of mito-
chondrial cholesterol capacity
following modulation of WT
TSPO and insertion of the
mutated isoform. (C) Control
MEFs and overexpressing WT
TSPO or TSPOD pretreated
(2 h) with vehicle DMSO,
MnTBAP (300 mM) or methyl-
b-cyclodextrin (300 mM) were
exposed to FCCP (20 mM) for
6 h. All cells were transfected
with Ub-GFP and immunos-
tained against ATP5B to distin-
guish mitochondria. (D) The
graph shows quantification of
ATP5B-Ub-GFP colocalization
coefficient; (n> 10 cells; P <
0.001). (E) Representative
images showing mtRFP:GFP-
LC3 colocalization in MEF cells
overexpressing TSPO after a
4 h expo-sure to the vehicle,
DMSO or FCCP, with and with-
out a 2-h pre-treatment with
MnTBAP. (F) Confocal micros-
copy depicts MEFs transfected
with PARK2-YFP (green) and
ATP5B (red) and overexpress-
ing either TSPO or TSPOD150–
158 after a 2-h exposure to the
vehicle DMSO or FCCP. (G) and
(H) report graphswith quantifi-
cation of mtRFP, GFP-LC3 and
PARK2-ATP5B quantifications
(n> 10 cells;
P< 0.001).
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of mitochondrial fission by tailoring the shape and dimensions of
the network in concert with the profusion proteins.61 DNM1L
accumulation in mitochondrial fractions was unaltered in the
cohorts of cells, indicating a TSPO-driven mechanism
independent from the standard pathways of mitochondrial
dynamics regulation (Fig. 6I).
Transmission electron microscopy studies permitted analysis
of the mitochondrial ultrastructure. In MEFs overexpressing
Figure 6. For figure legend, see page 2288.
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TSPO, we were able to quantify the number of mitochondria in
the perinuclear regions of the cell and found a significant increase
(22 § 0.73) compared to control (11 § 0.79) (Fig. 7A, B). As
shown in Fig. 7C, remodeling of cristae architecture was also
apparent in cells overexpressing TSPO (CTSPO). The number
of cristae per mitochondrion was quantified and plotted in
Fig. 7D (control: 10 § 0.60; CTSPO: 4 § 0.33). TSPO overex-
pression is therefore responsible for a tangible degeneration of
mitochondrial structure and ultrastructure. Since this is indepen-
dent from the anabolic pathways of mitochondrial biogenesis, it
is therefore an efficient readout of the defective catabolic mecha-
nisms for selection and removal of deficient mitochondria via
autophagy. Elucidating the molecular mechanisms by which
TSPO achieves this was our next goal of investigation.
In testing candidate mechanisms downstream of TSPO, co-
immunoprecipitation studies were employed to determine
whether a physical interaction occurs between TSPO and
VDAC1. In WT MEF cells endogenous VDAC1 co-immuno-
precipitated with TSPO (Fig. 8A). To assess the role of the
CRAC domain in TSPO-VDAC interaction, polyhistidine tag
affinity isolation experiments were performed in WT MEF cells
ectopically expressing either His-TSPO or His-TSPOD150–158.
VDAC1 copurified with TSPO in both conditions, indicating
the CRAC domain is not required for TSPO-VDAC1 interac-
tion (Fig. 8B). To further investigate the molecular partnering
between VDAC1 and TSPO and the importance of the TSPO:
VDAC ratio in mitophagy, LC3/mitochondria colocalization
experiments were repeated in VDAC1¡/¡ MEFs (Fig. 8E). 62
Although mitophagy could be triggered in VDAC1¡/¡ cells,
the response to FCCP was impaired (0.24 § 0.022; Fig. 8F)
compared to WT cells (0.45 § 0.060; Fig. S1D, E). This
reduced mitophagic response corresponded, as predicted, to an
increased accumulation of ROS in VDAC1¡/¡ cells (3.94 §
0.54) (Fig. 8C, D), compared to WT control cells (2.72 §
0.24). Although transient siRNA-mediated knockdown of
TSPO in VDAC1¡/¡ cells partially increased the mitophagic
response (0.37 § 0.026) to FCCP (Fig. 8E, F) a substantial res-
cue of the phenotype was not achieved. This molecular partner-
ing at the basis of TSPO-dependent regulation of mitophagy
was inspected further by re-inserting VDAC1 in VDAC1¡/¡
cells (Fig. S3C, D) and testing the rate of mitochondrial clear-
ance via western blot analysis of MT-CO1 (mitochondrially
encoded cytochrome c oxidase I) without and with FCCP
treatment. The transient knockin of VDAC1 yielded a restora-
tion of the inhibitory effect on mitophagy attributed to TSPO
as shown by the amount of MT-CO1 before and after FCCP
treatment (Fig. S3E).
Discussion
Here we provide evidence that the 18-kDa protein TSPO
interacts with VDAC1 contributing to the efficiency of mito-
chondrial quality control (Fig. 1 and 2) regulating both mito-
chondrial structure and function (Fig. 6 and 7), an effect which
goes beyond its regulation of cholesterol transport (Fig. 5).
Using co-immunoprecipitation and histidine (His)-tagged
affinity isolation assays, we demonstrate interactivity between
TSPO and VDAC1 thus confirming previous results40-42,63,64
and highlighting the relevance of the ratio of expression between
these 2 proteins for mitochondrial homeostasis (Figs. 6-8).
VDAC65,66 is fundamental for mitochondrial physiology67,68
impinging on various key aspects such as ATP synthesis,69,70 and
ROS production.20,21 We here demonstrate that when the ratio
of TSPO to VDAC1 increases, mitochondrial production of
ATP is limited and ROS levels are increased (Fig. 6), evidence
that is consistent with previous publications.10,20,21
By influencing the cellular redox system, TSPO blocks the
ubiquitination of mitochondrial proteins, essential for effective
recruitment of the autophagosomal machinery via SQSTM1.52
Cells largely devoid of TSPO show indeed an upregulation of
mitochondrial ubiquitination with the same being observed in
PRKCE¡/¡ MEFs (Fig. 4) in which TSPO expression is
downregulated.55
TSPO appears therefore to act downstream of the mitophagy
cascade, by impeding the transfer of poly-ubiquitin chains but
leaving both dissipation of the DCm and the accumulation/relo-
cation of PINK1 and PARK2 on mitochondria unaltered (Fig. 1,
2 and 3).71 Since PARK2 is fully able to translocate efficiently
despite the expression of TSPO (Fig. 3), we propose the modula-
tion of ROS to be the prominent mechanism by which TSPO
inhibits ubiquitination, although we could not exclude parallel
effects on alternative signaling pathways already linked to ubiqui-
tination efficiency (e.g., Ca2C).72 Accumulation of oxidative
stress promotes S-nitrosylation,73 which in turn regulates the
activation of PARK2.74,75
Figure 6 (See previous page). TSPO deregulates mitochondrial respiration as well as network morphology and size. (A) Reactive oxygen species genera-
tion was calculated by recording the rate of uptake of the O2
¡ sensitive dye dihydroethidium (DHE). Left panel depicts representative traces collected in
CF35 cells while (B) summarizes mean uptake rate (n > 10 cells; P < 0.001). (C) Mean traces representing accumulation of monochlorobimane-glutathi-
one (GSH) fluorescent conjugate (n D 5 cells; P < 0.05). (D) Representative traces as recorded by a luminometer in CF35 cells transfected with mitochon-
dria-targeted luciferase, and perfused with luciferin (20 mM) and ATP (100 mm). (E) Mean maximum luminescence is summarized (n D 3 cell
populations; P < 0.05;). (F) Real-time quantitative RT-PCR analysis of mRNA expression of genes encoding mitochondrial biogenesis transcription factors
in CF35 cells, Tfam (transcription factor A, mitochondrial) and Nrf1 (nuclear respiratory factor 1) (n> 4; p> 0.05). (G) Representative Z-stack maximum pro-
jection confocal images highlighting mitochondrial density in relation to the whole cell (CF35). Mitochondria are depicted by transfection with mt-GFP
(green) while the whole cell is visualized by loading cells with SNARF-1 (red) for 30 min. (H) Quantification of mitochondrial volume, calculated as a pro-
portion of the whole cell volume as analyzed by Volocity software (n > 20 cells; P < 0.01). (I) Western blot analysis of DNM1L levels in the mitochondrial
and cytosolic fractions of MEFs modulated for TSPO before and after treatment with FCCP (4 h). Membranes were also probed with ATP5B and GAPDH
as loading controls and TSPO to confirm TSPO modulation.
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Figure 7. The mitochondrial ultrastructure is undermined by TSPO. (A) Representative electron micrographs of the perinuclear region in MEFs in control
(left panel) and CTSPO conditions (right panel). (B) Graph to show numbers of mitochondria in the perinuclear region in control and CTSPO MEFs, (n D
27 cells; P < 0.001). (C) Representative electron micrographs of individual mitochondria in MEFs in control (left panel) and CTSPO conditions (right
panel). (D) Graph to show the average number of cristae per mitochondrion in control and CTSPO MEFs, (nD 18 cells; P < 0.001).
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Figure 8. The indispensable role of VDAC1 in the mitophagy inhibition by TSPO. (A) Cell lysates from WT MEFs were immunoprecipitated with anti-TSPO
antibodies and associated VDAC1 was detected with anti-VDAC1 antibodies by western blotting; VDAC1 co-immunoprecipitates with TSPO. Five% of the
lysate used for the immunoprecipitations was loaded for the input and probed with anti-VDAC1 (illustrating VDAC1 input) and anti-GAPDH (illustrating
total protein input). (B) Lysates from WT MEFs expressing His-Tagged TSPO were used in affinity isolation reactions. Isolated TSPO and VDAC1 were
detected with anti-TSPO and anti-VDAC1 antibodies by protein gel blotting. TSPO with the CRAC deletion is still able to interact with VDAC1. Five% of
the lysate used for the affinity isolation reaction was loaded for the input and probed with anti-VDAC1 (illustrating VDAC input) and anti-GAPDH (illustrat-
ing total protein input). ROS generation was calculated by recording the rate of uptake of the O2
¡-sensitive dye dihydroethidium (DHE). (C) Depicts rep-
resentative traces collected in MEFs while (D) summarizes mean uptake rate (P < 0.05; n > 10 cells). (E) Representative images of TSPO-modulated
VDAC1¡/- MEFs before and after treatment with FCCP (20 mM) for 4 h. A magnification of the merged images is shown in areas demarcated by the white
box. (F) Quantification of the degree of mtRFP:GFP-LC3 colocalization in VDAC1¡/¡MEFs (n> 15 cells; P < 0.05).
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VDACs have been reported to func-
tion as docking sites for PARK238 or as
a substrate for PARK2-mediated ubiq-
uitination39 but have been shown to be
dispensable for mitophagy.36 Our data
could therefore assist in elucidating the
ill-defined aspects of the contribution
of VDAC1 in mitophagy36,38,39 as the
existing controversy may be principally
due to, thus far, unconsidered variables
such as the differences in the VDAC1-
TSPO expression ratio which may nat-
urally occur among different cell types.
TSPO, VDAC1 and PARK2 could
therefore represent a molecular plat-
form for the tuning of autophagosome-
mediated removal of mitochondria
whose homeostatic expression ratio is
essential to avoid functional and struc-
tural corruption of mitochondria.
A larger mitochondrial network is
thus observed with TSPO overexpres-
sion that is not matched by: i) either
upregulation of mitochondrial biogene-
sis, or ii) alterations in expression of
pro-fission proteins (Fig. 6) but it is
instead accompanied by a paucity of
mitochondrial cristae that appear sparse
and malformed within the individual
mitochondrion (Fig. 7). Upregulation
of mitochondrial mass is an immediate
consequence of limited mitophagy (a
mismatch already seen in previous
work76), and likewise the respiratory
inefficiency and the increased oxidative
stress recorded in TSPO-overexpressing
cells. Nonetheless, the increased pro-
duction of ROS, to which we link the
inhibition of PARK2-mediated ubiqui-
tination, will in turn sustain the con-
stant re-expression of TSPO, driven by
the ROS-sensitive PRKCE,55 thus out-
lining a retrograde-like signaling path-
way77 in preventing mitochondrial quality control. In line with
this, FCCP-treated cells seem to present an accumulation of
TSPO, which could be a direct consequence of an increase in
ROS, triggered by the acute and irreversible uncoupling of mito-
chondria mediated by the protonophore.
In the final model, depicted in Fig. 9, we propose that TSPO,
via VDAC1, inhibits mitophagy by limiting the PARK2-depen-
dent ubiquitination of mitochondria for a concomitant accumu-
lation of ROS. This highlights further the pivotal role of the
molecules composing the OMM in the regulation of mitochon-
drial quality as flagged by the most recent advances in the
field.78,79
Materials and Methods
Cell culture, transfections, and gene expression
MEFs and CF35 were maintained at 37C under humidified
conditions, 5% CO2 and grown in Dulbecco’s modified Eagle
medium (Life Technologies, 11995065) supplemented with
10% fetal bovine serum (Life Technologies, 10082147), 100 U/
mL penicillin, and 100 mg/mL streptomycin (Life Technologies,
15140122). Cells plated on glass coverslips/10-cm dishes at a
30–50% confluence 1 d prior to transfection were transiently
transfected using a standard Ca2C phosphate method as described
previously.80 Cells were used in experiments 36–48 h post-
Figure 9. Proposed model for the regulation of cell mitophagy by the TSPO:VDAC1 expression ratio.
Working model for the regulation of mitophagy by TSPO and VDAC1. When TSPO expression is low rel-
ative to VDAC1, ROS production is reduced, which facilitates PARK2-mediated mitochondrial ubiquiti-
nation and results in recruitment of the autophagosomal machinery. Increasing the TSPO:VDAC1 ratio
leads to elevated ROS, which inhibits PARK2-mediated ubiqutination, SQSTM1 recruitment and
mitophagy.
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transfection. To knock down TSPO expression species-depen-
dent pre-designed siRNA was used (MEF target sequence:
ACCATTGGGCCTGCTGGTCTA (Qiagen, UK), CF35 tar-
get sequence: TCCTGGTCGCTGAACCTTCCA (Ambion,
UK), HeLa target sequence: CCCATCTTCTTTGGTG-
CCCGA (Qiagen, UK). As a control for these studies a nonsi-
lencing siRNA sequence (AllStars Negative Control, Qiagen,
1027281) was transfected. For overexpression studies, a
pcDNA3.1 (¡) construct containing the full murine Tspo cDNA
ORF, a generous gift from Prof. V. Papadopoulos (McGill Uni-
versity)81 was transfected; the empty vector was used as a control
in this instance. Experiments, unless otherwise indicated, were
performed in Dulbecco’s modified Eagle medium supplemented
with 10% fetal bovine serum or in the following saline solution
(recording solution, RM): 125 mM NaCl (S5886), 5 mM KCl
(P5405), 1 mM NaH2PO4 (S5011), 20 mM HEPES (H3784),
5.5 mM glucose (G7021), 5 mM NaHCO3 (S5761), and
1 mM CaCl2 (C7902), (all from Sigma-Aldrich, UK) pH 7.4.
Immunofluorescence
Cells were fixed in ice-cold acetone for 10 min at ¡20C, fol-
lowed by 3 £ 5 min washes in phosphate-buffered saline (PBS)
(Sigma-Aldrich, P4417). Where necessary, an antigen retrieval
step was carried out by boiling cells in citrate buffer pH 6.0
(Sigma-Aldrich, C9999) for 15 min, and allowing the sample to
cool to room temperature (RT). This was also followed by 3 £
5 min washes. Alternatively, cells were fixed in 4% paraformalde-
hyde (15 min, RT) (Sigma-Aldrich, P6148) and permeabilized
in 0.5% Triton-X (15 min, RT; Sigma-Aldrich, T9284). Block-
ing was carried out for 1 h at RT in 10% goat serum (Life Tech-
nologies,16210064) and 3% bovine serum albumin (Sigma-
Aldrich, A2153) in PBS (Sigma-Aldrich, P4417). Primary anti-
body incubations were conducted overnight for 16 h at 4 8C in
blocking solution as described. After a further wash step, second-
ary antibodies were incubated for 1 h in blocking solution, before
a final wash step. Cells were then mounted on slides with DAPI
mounting medium (Abcam, ab104139). Cells were stained with
the following primary antibodies: rabbit anti-TSPO (a generous
gift from Prof. Papadopoulos) 1:500; mouse anti-VDAC
(Abcam, ab14743) 1:500; anti-ATP5B (Abcam, ab14730)
1:1000; anti-SQSTM1 (Santa Cruz Biotechnologies, sc-25575)
1:500; anti-ubiquitin (Santa Cruz Biotechnology, sc-271289)
1:50, and the following secondary antibodies: anti-mouse Alexa
555 (Life Technologies, A21422) 1:1000; anti-rabbit Alexa 488
(Life Technologies, A11008) 1:1000 and anti-MT-CO1
(AbCam ab 14705) 1:1000.
ROS and GSH quantitative imaging
Dihydroethidium is sensitive to O2
¡ (superoxide) and may be
oxidized to the red fluorescent molecule ethidium. Once oxi-
dized, ethidium binds to DNA, which results in the amplification
of the red signal, within the nucleus. The rate at which the signal
increases in intensity is dependent on cytosolic levels of O2
¡,
thereby enabling the quantification of ROS levels within the cell.
Cells were transferred to the Zeiss LSM 510 confocal microscope
and 5 mM DHE (Life Technologies, D11347), diluted in RM,
was added and the increase in fluorescence intensity was mea-
sured through continuous recording for at least 10 min. For
GSH measurements, cells were incubated with 2 mM mono-
chlorobimane (Life Technologies, M-1381MP) in RM: z-stacks
were then acquired at regular intervals to follow the time course
of loading over 30 min periods or until a steady state was
reached. Maximum intensity projections were used to obtain val-
ues for MCB intensity at each time point.
Mitochondrial ATP measurements
A luciferin-luciferase assay was used to measure basal and real-
time Ca2C-induced ATP production. CF35 cells were transfected
with mitochondrially-targeted luciferase, which catalyzes the
ATP-dependent oxidation of luciferin, resulting in light emis-
sion. Cells were first perfused with RM supplemented with
20 mM luciferin (Life Technologies, L2912) and alterations in
bioluminescence were recorded using a custom-built luminome-
ter (Cairn Research, Faversham, Kent, UK). When the trace sta-
bilized, cells were immediately perfused with RM supplemented
with 20 mM luciferin and 100 mM ATP (Sigma-Aldrich,
A7699). Application of extracellular ATP triggers real-time
Ca2C-induced mitochondrial ATP production.
RNA isolation, cDNA synthesis and quantitative real time
PCR
Total RNA was extracted from the cultured cells using Tri-
Reagent (Sigma-Aldrich, T9424) and purified using an RNeasy
Mini Kit (Qiagen, 74104). Spectrophotometry was used to quan-
tify and check the purity (260/280nm ratio) of the total RNA
(Nanodrop, LabTech, East Sussex, UK). One microgram of total
RNA was used to synthesize cDNA in a 20-mL reaction volume
as described using the QuantiTect Reverse Transcription kit
(Qiagen, 204141). Gene transcripts were amplified by RT-PCR
using the specific primers: TSPO, GGTCTGGAAAGAGC-
TGGG, GGCCCAACCCATTTGT-CG; NRF1,
ATGTGTTTGAGTCTAATC, AGATACAGAGGACAAT-
AG; TFAM AAGCCTCTGACTTCA-TAC, GCCCTATAAG-
CATCTT-CA.
Quantitative real-time PCR reactions were performed in the
Chromo 4 light cycler (Bio-Rad, Hemel Hempstead, UK). The
absolute quantification method was used whereby the level of
gene expression was expressed as copy numbers. A standard curve
was generated using known amounts of the DNA PCR product
of the gene. A volume of 2 mL of the cDNA product from the
reverse transcription reaction was used in a total volume of
20 mL SYBR green detection (Qiagen, 204141). The SYBR
green PCR reaction mix consisted of a final concentration of
2.5 mM MgCl2, 0.1 mM of each primer, with the reaction con-
sisting of the following: an initial 15 min denaturation step at 95
8C followed by denaturation at 94 8C for 15 sec, annealing at 55
8C for 25 sec and extension at 72 8C for 15 sec repeated for 40
cycles. The DNA standards and samples were run in the same
96-well PCR plate and the average of each duplicate value was
used for subsequent statistical analyses. All PCR products were
checked for specificity and purity from a melting curve profile
performed by the lightcycler software at the end of each run.
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Mitochondrial volume and quantification of mitophagy
CF35 cells were transfected with mt-GFP to visualize mito-
chondria. 36–48 h post-transfection, cells were loaded for
30 min at 37 8C with carboxy-snarf-1-a.m. (SNARF-1, 10 mM;
Life Technologies, C1271), a red dye that stains the cytosol. Z-
stacks were acquired using the Leica SP5 confocal microscope
(x63 objective). Analysis was performed using Volocity software
to determine the volume of the cell (SNARF-1) and of mito-
chondria (mt-GFP). CF35 and MEF cells, cotransfected with
GFP-LC3, which is expressed on autophagosomes, and mtRFP,
to visualize mitochondria, were harvested 36–48 h post-transfec-
tion and transferred to a Leica SP5 confocal microscope (x63
objective). Images were acquired of individual transfected cells at
high magnification before and after application of FCCP
(Sigma-Aldrich, C2920). Colocalization coefficients were calcu-
lated as a modified version of the binary intersection coefficient
using ImageJ software (NIH). Images were first thresholded so
that residual homogenous GFP signal was not considered, leaving
only the bright green fluorescent puncta, indicative of autopha-
gosomes. Background was also removed from mitochondrial
channels. The images were then made binary in ImageJ, and
objects were identified, enabling the area of each to be deter-
mined. Using the merged image, GFP-LC3 objects that fully or
partially overlapped mitochondria were identified empirically.
The final coefficient was calculated by dividing the summed area
of these objects by the total mitochondrial area. Mitochondrial
aggregation coefficients were calculated by the mean intensity of
mtRFP signal/total area of mitochondria from sum z-projections
of cells, with the same number of slices for each image. The
intensity of the cumulative mtRFP signal will be higher within a
smaller mitochondrial area indicating greater aggregation. Since
transfection yields individual cells with unequal levels of overex-
pression or knockdown of the gene of interest, controlled sam-
pling was carried out in order to select cells for imaging. Cells
were selected that had levels of cotransfected reporter fluores-
cence that could be detected using the same settings on the
microscope, therefore all falling into a small mean intensity
range.
DCm measurements
Cells cotransfected with YFP were loaded with 75 nM tetra-
methyl rhodamine methyl ester (TMRM; Sigma-Aldrich,
T5428) and 10 mM verapamil HCl (Sigma-Aldrich, V4629;
which is required to inhibit TMRM export from the cell via the
multidrug transporter82) in HEPES-buffered salt solution
(156 mM NaCl, 3 mM KCl, 2 mM MgSO4 [Sigma, M2643],
2 mM CaCl2, 10 mM glucose; 10 mM HEPES [Sigma-Aldrich,
H4034]). TMRM accumulates in mitochondria, and its signal
intensity is a function of membrane potential.83 Cells were
allowed to equilibrate the dye for at least 30 min at room tem-
perature before they were transferred to a Zeiss LSM 510 confo-
cal microscope (40X objective) for imaging. Fields of transfected
cells were selected before time series imaging. After several min
of continuous recording at basal conditions, 20 mM FCCP was
added to induce depolarization. Settings were kept constant
between experiments. Mitochondrial regions of interest were
demarcated and the corresponding TMRM fluorescence intensi-
ties calculated.
Protein extraction, mitochondrial isolation, and cross-linking
Cells grown on 10-cm plates were harvested, dissolved in
1 mL of lysis buffer (50 mM Tris [Sigma-Aldrich, T6066] pH
8.0, 150 mM NaCl, 1% Triton-X [Sigma-Aldrich, T9284], pro-
tease inhibitor [Roche, 04693132001]) and left on ice for
20 min. Cell debris was removed by centrifugation at 17,000 g
for 20 min, leaving the whole cell lysate. For mitochondrial isola-
tion, 500 mL fractionation buffer (250 mM sucrose, 20 mM
HEPES, pH 7.4, 10 mM KCl, 1.5 mM MgCl2 [Sigma-Aldrich,
M4880], 1 mM EDTA [Sigma-Aldrich, E6758], 1 mM EGTA
[Sigma-Aldrich, E3889], protease inhibitor) was added to MEF
cells growing on 10-cm plates. Plates were scraped immediately
and the cell suspension was then passed through a 26-gauge nee-
dle 12 times before centrifuging at 700 g for 5 min. The result-
ing supernatant fraction was subjected to a further centrifugation
at 10000 g to obtain the mitochondrial pellet, which was resus-
pended in lysis buffer. Cross-linking was performed by treating
cells with 1 mM dithiobis[succinimidyl propionate (Thermo Sci-
entific, 22586), 10 mM N-ethylmaleimide (Thermo Scientific,
23030) in PBS for 1 h on ice; this was then inactivated with
10 mM glycine (Sigma-Aldrich, G8898), 10 mM N-ethylmalei-
mide in PBS for 5 min.
Gel electrophoresis and immunoblotting analyses
Sample proteins were quantified using a bicinchoninic acid
protein assay kit (Thermo Scientific, 23227). Equal amounts of
protein (25 mg for whole cell lysates/cytosolic fractions; 10 mg
for mitochondrial fractions) were resolved on any kD TGX
TM
(Bio-Rad, Hemel Hempstead, UK), 10 or 12% polyacrylamide
gels and transferred to nitrocellulose membranes. The mem-
branes were blocked in 2% nonfat dry milk in TBST (50 mM
Tris, 150 mM NaCl, 0.05% Tween 20 [Sigma-Aldrich, P2287],
pH 7.5) for 1 h then incubated with the appropriate diluted pri-
mary antibody at 48C overnight: anti-TSPO (Abcam ab109497)
1:10000; anti-ATP5B (Abcam, ab14730) 1:10000; anti-
GAPDH:Hrp conjugated 1:5000 (Abcam ab9482); anti-ubiqui-
tin (Abcam ab7254) 1:1000. Membranes were washed in TBST
(3 £ 15 min at RT) and then incubated with the corresponding
peroxidise-conjugated secondary antibodies for 1 h at RT. After
further washing in TBST, blots were developed using an ECL
Plus protein gel blotting detection kit (Amersham, RPN2133).
Immunoreactive bands were analyzed by performing densitome-
try with ImageJ software.
Immunoprecipitation
Wild-type MEFs were incubated with 20 mM FCCP or an
equivalent DMSO vehicle control for 4 h at 37C with 5%
CO2. Cells were washed once in PBS then lysed by 60 passes
through a 25-gauge needle in lysis buffer (20 mM Tris, 100 mM
NaCl, pH 7.5) at 4C. Unbroken cells and nuclei were removed
by centrifugation at 2600 g for 5 min. Supernatant fractions
were immunoprecipitated using a dynabead co-immunoprecipi-
tation kit (Invitrogen, 14321D) following the manufacturer’s
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instructions. Briefly, for each reaction 5 mg of anti-TSPO anti-
body was coupled to 1.5 mg of dynabeads using the provided
coupling solutions overnight at 37C. For negative control con-
ditions beads were subjected to the same procedure in the absence
of anti-TSPO. Supernatant fractions were mixed with the anti-
body-coupled beads and incubated for 1 h at 4C with end-over-
end mixing. Complexes were eluted by boiling the washed beads
in SDS-PAGE loading buffer. Proteins were resolved on 12%
SDS-PAGE gels, transferred onto nitrocellulose membranes, and
detected with anti-VDAC (Abcam ab14743), anti-TSPO
(Abcam ab109497) and anti-GAPDH (Abcam ab9482)
antibodies.
His-Tag affinity isolation
Wild-type MEFs were transfected with polyhistidine-tagged
TSPO, polyhistidine-tagged TSPOD150–158, or YFP as the nega-
tive control. After 48 h cells were washed once in PBS then lysed
by 60 passes through a 25 gauge needle in lysis/wash buffer
(20 mM Tris, 100 mM NaCl, 30 mM imidazole [Sigma-
Aldrich, I5513], 5 mM MgCl2, 130 mM CaCl2, pH 7.5) at
4C. Unbroken cells and nuclei were removed by centrifugation
at 2600 g for 5 min. Supernatant fractions were subsequently
treated with 50 units of DNAse 1 (Promega, M6101) for 30 min
at 37C. The affinity isolation reaction was performed using
Dynabeads His-Tag Isolation & Pulldown kit (Life Technolo-
gies, 10103D) following the manufacturer’s protocol. Briefly,
supernatant fractions were mixed with 1 mg of beads and incu-
bated for 30 min at 4C with end-over-end mixing. Beads were
washed 4 times with lysis/wash buffer; complexes were eluted by
boiling the washed beads in SDS-PAGE loading buffer. Proteins
were resolved on 12% SDS-PAGE gels, transferred onto nitrocel-
lulose membranes, and detected with anti-VDAC (Abcam
ab14743), anti-TSPO (Abcam ab109497) and anti-GAPDH
(Abcam ab9482) antibodies.
EM analysis
Transfected MEFs grown on melinex plastic-film (Agar Scien-
tific, AGL4103) were identified by fluorescence microscopy and
their localization marked on the plastic. Cells were fixed with
phosphate-buffered 2.5% glutaraldehyde with 0.1 M sodium
phosphate for 1 h. Cells were then treated with 1% osmium
tetroxide in hydrogen peroxide for 1 h, dehydrated with acetone,
and embedded with epon (Agar Scientific, R1045). Electron
micrographs were taken with a 2 JEOL 1010 transmission elec-
tron microscope. Acquired images were analyzed using ImageJ
and "Lucida" (Kinetic Imaging) to characterize precise
mitochondrial size distributions and to threshold and binarize
the images, allowing quantification of the volume of a mitochon-
drion occupied by cristae as the proportion of total pixels occu-
pied by a mitochondrion that were below the threshold. The
software was also used to define the number of cristae per mito-
chondrion and per 1 mm2.
Statistical analysis
Data are presented as mean § standard error of the mean.
One-way or 2-way analysis of variance (ANOVA) were used in
multiple group comparisons with Tukey’s post hoc test to com-
pare 2 data sets within the group and a p value less than 0.05 was
considered significant. All analyses were performed in GraphPad
Prism 6.0.
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